

# Supplementary Information




Figure S1.  $^1\text{H}$  NMR spectrum of compound **1** ( $\text{CDCl}_3$ , 500.13 MHz).







Figure S2. COSY spectrum of compound **1** ( $\text{CDCl}_3$ , 500.13 MHz).




**Figure S3.**  $^{13}\text{C}$  NMR spectrum of compound **1** ( $\text{CDCl}_3$ , 125.8 MHz).



**Figure S4.** HSQC spectrum of compound **1** ( $\text{CDCl}_3$ , 500.13 MHz).



**Figure S5.** HMBC spectrum of compound **1** (CDCl<sub>3</sub>, 500.13 MHz).



**Figure S6.** NOESY spectrum of compound **1** (CDCl<sub>3</sub>, 500.13 MHz).




Figure S7.  $^1\text{H}$  NMR spectrum of compound **2** ( $\text{CDCl}_3$ , 500.13 MHz).







Figure S8.  $^{13}\text{C}$  NMR spectrum of compound **2** ( $\text{CDCl}_3$ , 125.8 MHz).




**Figure S9.** COSY spectrum of compound **2** (CDCl<sub>3</sub>, 500.13 MHz).




**Figure S10.** HSQC spectrum of compound **2** (CDCl<sub>3</sub>, 500.13 MHz).




**Figure S11.** HMBC spectrum of compound **2** (CDCl<sub>3</sub>, 500.13 MHz).




**Figure S12.** NOESY spectrum of compound **2** (CDCl<sub>3</sub>, 500.13 MHz).




**Figure S13.** <sup>1</sup>H NMR spectrum of compound **3** (DMSO, 300.13 MHz).




**Figure S14.** COSY spectrum of compound **3** (DMSO, 300.13 MHz).




**Figure S15.**  $^{13}\text{C}$  NMR spectrum of compound **3** (DMSO, 75.47 MHz).




**Figure S16.** HSQC spectrum of compound **3** (DMSO, 300.13 MHz).



**Figure S17.** HMBC spectrum of compound **3** (DMSO, 300.13 MHz).



**Figure S18.** NOESY spectrum of compound **3** (DMSO, 300.13 MHz).



**Figure S19.** Chromatogram of the acidic hydrolysate of compound **2**. Chromatographic conditions: column, Chirobiotic T; mobile phase, MeOH:H<sub>2</sub>O:CH<sub>3</sub>CO<sub>2</sub>H (70:30:0.02 v/v/v); flow rate, 0.5 mL/min; detection, 210 nm.

**Table S1.** Chiral HPLC analysis of the acidic hydrolysate of compound **2** \*.

	Retain Time (min)
L-valine	6.60
D-valine	8.32
L-alanine	7.16
D-alanine	9.36
L-leucine	6.78
D-leucine	9.67
L-pipecolic acid	8.68
D-pipecolic acid	14.67
N-methyl-L-leucine	8.09
Acidic hydrolysate of <b>2</b>	6.59, 7.20, 8.09, 8.83, 9.67, 10.57, 14.69
Acidic hydrolysate of <b>2</b> + DL-valine (coinjection)	6.61, 7.31, 8.30, 8.10, 8.84, 9.70, 10.50, 14.95
Acidic hydrolysate of <b>2</b> + DL-alanine (coinjection)	6.59, 7.19, 8.04, 8.81, 9.37, 9.70, 10.50, 14.90
Acidic hydrolysate of <b>2</b> + DL-leucine	6.60, 6.76, 7.26, 8.04, 8.83, 9.67, 10.54, 15.02
Acidic hydrolysate of <b>2</b> + DL-pipecolic acid (coinjection)	6.58, 7.20, 8.09, 8.64, 8.84, 9.77, 10.64, 14.64
Acidic hydrolysate of <b>2</b> + N-methyl-L-leucine (coinjection)	6.59, 7.20, 8.09, 8.83, 9.67, 10.57, 14.69

\* Chromatographic conditions: column, Chirobiotic T; mobile phase, methanol:water:acetic acid (70:30:0.02 v/v/v); flow rate, 0.5 mL/min; detection, 210 nm.